Higher patient cost-sharing is associated with a lower likelihood of treatment augmentation in patients with depression who are treated with antidepressants.
Robert A. Forbes, PhD
Advertisement
Articles by Robert A. Forbes, PhD
In treatment of depression with adjunctive aripiprazole, early improvement (week 2) was a significant predictor of remission, and lack of improvement was associated with nonremission.
Advertisement
Latest Updated Articles
- Adjunctive Aripiprazole for Depression: Predictive Value of Early Assessment
Published: December 22nd 2011 | Updated:
- Impact of Cost-Sharing on Treatment Augmentation in Patients With Depression
Published: January 16th 2012 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Leucovorin Treatment Expansion for Autism Symptoms Under FDA Review
2
FDA Approves Imlunestrant for ER+ and HER2-Negative Breast Cancer
3
Marathon Health, Medbridge Partner to Launch Integrated Virtual MSK Care Program
4
In Primary Care–Oncology Collaboration, the Baton Goes Both Ways
5
